What Is De Novo Lipogenesis?

De novo lipogenesis (DNL) is the metabolic process by which the body synthesises new fatty acids from non-fat precursors — primarily excess carbohydrates. The term "de novo" means "from new" or "from the beginning," reflecting that these fats are created from scratch rather than absorbed from dietary fat. What is de novo lipogenesis in practical terms? It is the body's mechanism for converting surplus sugar into storable fat.

From an evolutionary standpoint, de novo lipogenesis served a critical survival function. During periods of seasonal food abundance (such as autumn fruit availability), DNL allowed our ancestors to convert excess carbohydrates into dense, long-term energy reserves — body fat — that could sustain them through winter famine and cold exposure. This was an adaptive, intermittent process: DNL activated during brief periods of carbohydrate surplus, then shut down during fasting and scarcity (Ameer et al., 2014).

The problem in the modern environment is that the conditions that activate DNL — high carbohydrate intake, constant feeding, elevated insulin — have become permanent rather than seasonal. The 24/7 availability of calorie-rich, sugar-laden food means DNL can remain chronically active, turning the liver into what researchers describe as a "fat factory." This is particularly consequential because the primary dietary activator of DNL is fructose — a sugar that bypasses the regulatory mechanisms governing glucose metabolism entirely. The result is a metabolic pathway designed for occasional energy storage that now drives chronic disease: fatty liver, insulin resistance, elevated triglycerides, and the constellation of conditions known as metabolic syndrome.

Where Does De Novo Lipogenesis Occur?

Where does de novo lipogenesis occur in the human body? DNL takes place primarily in two tissues, with the liver dominating in adults:

• The liver (hepatic DNL): This is the primary site of de novo lipogenesis in humans and the most clinically significant location. What is hepatic de novo lipogenesis? It is the synthesis of new fatty acids specifically within liver cells (hepatocytes). The liver receives the highest concentration of dietary fructose via the portal vein from the gut, making it ground zero for fructose-driven fat synthesis. When hepatic DNL is chronically elevated, the triglycerides it produces either accumulate within liver cells (causing fatty liver) or are exported into the bloodstream as VLDL particles (causing elevated blood triglycerides).
• Adipose tissue (fat tissue DNL): Fat cells also possess the enzymatic machinery for de novo lipogenesis, though adipose DNL is substantially less active than hepatic DNL in adult humans. Adipose DNL plays a more significant role during infancy and in response to prolonged carbohydrate overfeeding. In obesity, adipose tissue DNL may paradoxically decrease as fat cells become insulin resistant.
• Other tissues: Under specific conditions, DNL can occur in the kidneys, brain, and certain cancer cells. Cancer cells often upregulate DNL to fuel rapid membrane synthesis — a phenomenon explored in research on how targeting energy metabolism may support cancer treatment strategies.

The liver's dominance in DNL explains a critical clinical observation: people can develop significant fatty liver disease while consuming a "low-fat" diet — because the fat in their liver was not consumed as dietary fat but was manufactured from carbohydrates through hepatic de novo lipogenesis. This is why the "sugar diet" illusion creates hidden metabolic health risks that a calorie-counting approach misses entirely.

When Does De Novo Lipogenesis Occur?

When does de novo lipogenesis occur? Under normal metabolic conditions, DNL is activated in the fed state — after consuming carbohydrate-rich meals — and is suppressed during fasting. The timing and intensity of DNL depend on several factors:

• Glycogen saturation: DNL becomes most active when glycogen stores in the liver (~100g) and muscles (~400g) are already full. Once glycogen storage capacity is exceeded, surplus carbohydrates have no option other than conversion to fat through DNL. This is why people who eat frequent carbohydrate-rich meals without depleting glycogen through exercise experience chronic DNL activation.
• Insulin levels: Insulin is the primary hormonal activator of DNL. It stimulates the transcription factor SREBP-1c (sterol regulatory element-binding protein 1c), which upregulates the expression of DNL enzymes including ACC and FAS. Chronically elevated insulin — the hallmark of insulin resistance — keeps DNL active even between meals.
• Fructose — the exception: Unlike glucose, fructose activates DNL regardless of glycogen status or energy needs. Because fructose metabolism by fructokinase is unregulated and bypasses insulin signalling, fructose-driven DNL occurs immediately upon hepatic fructose delivery — even in a fasted state, even when energy stores are full. This is what makes fructose the most potent dietary activator of de novo lipogenesis.
• Circadian influence: DNL enzymes follow circadian rhythms, with higher activity in the late afternoon and evening. This means carbohydrate-rich meals consumed later in the day may drive more DNL than identical meals consumed in the morning — a finding relevant to meal timing strategies.

In the modern dietary environment — characterised by frequent meals, snacking, high fructose intake, and sedentary behaviour — the conditions that activate DNL are essentially permanent. The metabolic switch that evolved to be flipped briefly during seasonal abundance now stays on continuously, explaining why fructose has become the primary driver of the silent fatty liver epidemic.

The De Novo Lipogenesis Pathway: Step by Step

The de novo lipogenesis pathway is a series of enzymatic reactions that converts excess carbohydrates into fatty acids, which are then assembled into triglycerides for storage. Understanding this pathway reveals both why DNL can become dangerous and where it can be intervened upon.

The pathway begins with the breakdown of carbohydrates to pyruvate through glycolysis. From there, the key steps involve mitochondrial processing, cytoplasmic fatty acid assembly, and final triglyceride formation. The two rate-limiting enzymes — acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS) — serve as the primary regulatory and intervention points in the de novo lipogenesis pathway.

Critically, the pathway diverges depending on the carbohydrate source. When glucose is the substrate, DNL is regulated by multiple checkpoints: phosphofructokinase controls glycolysis, glycogen synthesis diverts surplus glucose, and insulin sensitivity modulates enzyme activity. When fructose is the substrate, all of these checkpoints are bypassed — fructose is rapidly converted to fructose-1-phosphate by fructokinase, then split by aldolase B into glyceraldehyde and DHAP, which feed directly into the lipogenic pathway.

GLUCOSE VS FRUCTOSE AS DE NOVO LIPOGENESIS SUBSTRATES

Why Fructose Is the Most Potent DNL Activator

Among all dietary carbohydrates, fructose is uniquely lipogenic — meaning it preferentially drives fat synthesis rather than energy production. Controlled overfeeding studies consistently demonstrate that fructose increases hepatic de novo lipogenesis rates 3–5 times more than equivalent caloric loads of glucose (Stanhope et al., 2009; Schwarz et al., 2015).

The mechanism is rooted in fructose's unique metabolic pathway:

• Unregulated fructokinase activity: The enzyme fructokinase (ketohexokinase, KHK-C) phosphorylates fructose to fructose-1-phosphate without any metabolic feedback control. No matter how much energy the cell already has, fructokinase continues processing fructose at full speed. This is why understanding the forgotten enzyme behind sugar damage is central to understanding de novo lipogenesis.
• ATP depletion and uric acid generation: The unregulated phosphorylation rapidly depletes ATP, generating AMP that is catabolised to uric acid via the purine degradation pathway. Uric acid itself promotes oxidative stress, mitochondrial dysfunction, and inflammation — compounding the metabolic damage.
• AMPK suppression: Fructose actively suppresses AMP-activated protein kinase (AMPK) — the master metabolic enzyme that normally inhibits de novo lipogenesis (by phosphorylating and inactivating ACC). With AMPK suppressed, the DNL brakes are released and fat synthesis accelerates.
• SREBP-1c activation: Fructose metabolism activates SREBP-1c and ChREBP — transcription factors that upregulate the expression of all DNL enzymes (ACC, FAS, SCD1) — effectively increasing the liver's capacity to manufacture fat.

Even when dietary fructose is eliminated, the body can generate fructose internally through the polyol pathway (aldose reductase converts glucose → sorbitol → fructose). This endogenous fructose production activates the same DNL-driving pathway — which is why high blood glucose levels can still fuel fatty liver even in someone consuming no dietary sugar (Lanaspa et al., 2013).

Crucially, table sugar (sucrose) delivers 50% fructose and 50% glucose simultaneously, while high-fructose corn syrup delivers approximately 55% fructose. Every serving of these sweeteners directly fuels hepatic de novo lipogenesis — a connection that explains why sugar-sweetened beverage consumption is the strongest dietary predictor of fatty liver disease.

Health Consequences of Chronic De Novo Lipogenesis

When de novo lipogenesis is chronically activated — as it is in the modern dietary environment of constant fructose and refined carbohydrate exposure — the consequences extend far beyond simple weight gain. The triglycerides produced by DNL either accumulate in liver cells or are exported into the bloodstream, creating a cascade of metabolic dysfunction:

METABOLIC CONSEQUENCES OF CHRONIC DE NOVO LIPOGENESIS

How to Reduce De Novo Lipogenesis

Reducing chronically elevated de novo lipogenesis requires addressing its upstream drivers — particularly fructose exposure, insulin elevation, and AMPK suppression. The goal is not to eliminate DNL entirely (it remains a normal physiological process) but to return it to the intermittent, regulated pattern it was designed for.

STRATEGIES TO REDUCE CHRONIC DE NOVO LIPOGENESIS

The DNL–Insulin Resistance Vicious Cycle

One of the most clinically important aspects of de novo lipogenesis is the self-reinforcing feedback loop it creates with insulin resistance:

Stage 1 — DNL creates liver fat: Excess fructose (dietary or endogenous) is converted to triglycerides through hepatic DNL, depositing fat in liver cells.

Stage 2 — Liver fat causes insulin resistance: Hepatic fat accumulation directly impairs insulin receptor signalling in liver cells. The liver becomes resistant to insulin's instruction to suppress glucose output.

Stage 3 — Insulin resistance drives hyperinsulinemia: The pancreas compensates by producing more insulin to overcome the liver's resistance, creating chronically elevated insulin levels.

Stage 4 — Hyperinsulinemia stimulates more DNL: High insulin activates SREBP-1c, which upregulates all DNL enzymes — increasing the liver's fat-manufacturing capacity. More DNL → more liver fat → more insulin resistance → more insulin → more DNL.

This is why people with established insulin resistance and fatty liver find it so difficult to reverse these conditions through simple calorie restriction alone. Breaking this cycle requires targeting the upstream drivers — particularly fructose metabolism and AMPK activation — rather than simply reducing overall food intake. This is the principle behind evidence-based approaches to stimulating genuine fat loss at the metabolic level. Our companion article offers a deeper perspective on luteolin's role as a natural warrior against the metabolic syndrome cascade.

Why "Low-Fat" Diets Miss the Point

One of the most consequential misunderstandings in nutrition has been the assumption that dietary fat is the primary cause of body fat accumulation. This led to decades of "low-fat, high-carbohydrate" dietary guidelines — which paradoxically increased de novo lipogenesis and accelerated the epidemics of fatty liver, obesity, and type 2 diabetes.

The key insight is that the fat accumulating in the liver and around the organs of metabolically unhealthy individuals is largely manufactured from carbohydrates through DNL — not absorbed from dietary fat. A "low-fat" diet that replaces fat calories with refined carbohydrates and added sugars can actually increase hepatic DNL and worsen metabolic outcomes.

Research by Schwarz et al. (2017) demonstrated that in patients with NAFLD, hepatic de novo lipogenesis contributed approximately 26% of total liver triglyceride — a dramatically higher rate than the ~5% observed in metabolically healthy individuals. This was driven almost entirely by carbohydrate and fructose intake, not dietary fat.

This understanding has profound implications for dietary approaches. Rather than focusing on fat restriction, metabolic health strategies should prioritise reducing the substrates and hormonal drivers of DNL: limit fructose and refined carbohydrates, improve insulin sensitivity, and support the body's ability to switch between fuel sources — a capacity known as metabolic flexibility. For practical guidance on understanding carbohydrates through a metabolic lens, see our article on how blood sugar spikes and crashes fuel the cravings that perpetuate DNL activation.

When to seek medical evaluation: If you have been diagnosed with fatty liver disease, elevated triglycerides, insulin resistance, or metabolic syndrome — or if you experience persistent fatigue, unexplained weight gain around the abdomen, or difficulty losing weight despite dietary effort — consult a healthcare provider for comprehensive metabolic testing including liver function panels, fasting insulin, HOMA-IR, uric acid, and lipid panels. Early identification of chronic de novo lipogenesis activation allows intervention before progression to NASH, fibrosis, or type 2 diabetes. This content is for informational purposes only and does not constitute medical advice.

References

• Ameer, F., Scandiuzzi, L., Hasnain, S., Kalbacher, H., & Zaidi, N. (2014). De novo lipogenesis in health and disease. Metabolism, 63(7), 895–902.
• Hannou, S. A., Haslam, D. E., McKeown, N. M., & Herman, M. A. (2018). Fructose metabolism and metabolic disease. Journal of Clinical Investigation, 128(2), 545–555.
• Lanaspa, M. A., Ishimoto, T., Li, N., et al. (2013). Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome. Nature Communications, 4, 2434.
• Schwarz, J. M., Noworolski, S. M., Wen, M. J., et al. (2015). Effect of a high-fructose weight-maintaining diet on lipogenesis and liver fat. Journal of Clinical Endocrinology & Metabolism, 100(6), 2434–2442.
• Schwarz, J. M., Noworolski, S. M., Erkin-Cakmak, A., et al. (2017). Effects of dietary fructose restriction on liver fat, de novo lipogenesis, and insulin kinetics in children with obesity. Gastroenterology, 153(3), 743–752.
• Softic, S., Stanhope, K. L., Boucher, J., et al. (2020). Fructose and hepatic insulin resistance. Critical Reviews in Clinical Laboratory Sciences, 57(5), 308–322.
• Song, Z., Xiaoli, A. M., & Yang, F. (2018). Regulation and metabolic significance of de novo lipogenesis in adipose tissues. Nutrients, 10(10), 1383.
• Stanhope, K. L., Schwarz, J. M., Keim, N. L., et al. (2009). Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. Journal of Clinical Investigation, 119(5), 1322–1334.